

GenCore version 5.1.3
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 24, 2003, 10:13:33 : Search time 763.054 Seconds
(without alignments)
10583.354 Million cell updates/sec

Title: US-09-922-895-3

Perfect score: 3586

Sequence: 1 GCATCCCTACCTCTCCCATC.....CTATCAGCAGGAGAGTGAA 3586

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N.Geneseq_101002:*

1: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SID52/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SID52/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the total score being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	3586	100.0	5099	18	AAT93601 Human eosinophil e
2	2406	67.1	7201	24	ABL32337 Human immune syste
3	2271.8	63.4	7201	24	ABL32336 Human immune syste
4	344.2	9.6	1915	18	AAT85162 Human chemokine re
5	209	5.8	3660	22	ABA17973 Human nervous syst
6	209	5.8	3662	22	ABA17972 Human nervous syst
7	208.2	5.8	235033	19	AAV57926 Hereditary haemoch
8	206.2	5.8	11901	20	AAK02938 Human TL-Ira BAC c
9	206.2	5.8	42299	22	AAK68932 Human immune/haema

C 10	206	5.7	3417	22	AAH18467 Human cDNA sequenc
C 11	205.4	5.7	1273	22	ABA21094 Human nervous syst
C 12	205	5.7	1376	21	AAK99845 Human secreted pro
C 13	205	5.7	10800	22	AAK83329 Human immune/haema
C 14	205	5.7	29629	24	ABL58699 Human kinase encod
C 15	204.8	5.7	20601	22	AAK79760 Human immune/haema
C 16	204.2	5.7	8676	22	ABA07159 Human pancreatic c
C 17	204.2	5.7	31931	22	ABA07160 Human pancreatic c
C 18	204	5.7	1717	24	ABL67066 Thyroid cancer rel
C 19	204	5.7	1717	24	AAD25221 Human chemokine (C
C 20	204	5.7	58708	22	AAK64739 Human neuroblastom
C 21	203.8	5.7	2607	22	AAF97848 Human immune/haema
C 22	203.8	5.7	4258	22	AAK68397 Human immune/haema
C 23	203.8	5.7	23815	22	AAK68678 Human immune/haema
C 24	203.8	5.7	23815	22	AAK85169 Human immune/haema
C 25	203.4	5.7	1739	22	AAK75554 Human immune/haema
C 26	203.4	5.7	1739	22	AAK75555 Human chemokine (C
C 27	203.2	5.7	1717	24	AAK35929 Human musculoskele
C 28	203	5.7	4862	22	AAK35929 Human secreted pro
C 29	202.8	5.7	2824	21	AAK59843 Human small induci
C 30	202.6	5.6	10012	24	ABL55889 Human novel protei
C 31	202.6	5.6	13021	22	AAK16553 Human CDNA sequenc
C 32	202.6	5.6	13021	22	AAH18257 Human immune/haema
C 33	202.4	5.6	2345	22	AAK85378 Human nervous syst
C 34	202.4	5.6	3985	22	AAK22319 Human digestive sy
C 35	202.2	5.6	32186	22	AAK89692 Human digestive sy
C 36	202.2	5.6	32186	22	AAK75080 Human schizophre
C 37	202.2	5.6	44848	21	AAK509301 Human chromosome 1
C 38	202.2	5.6	319608	22	AAH51601 Human Oestrogen re
C 39	201.8	5.6	319608	21	AAH51601 Human immune/haema
C 40	201.8	5.6	325791	22	AAK43104 Human high bone ma
C 41	201.6	5.6	21777	22	AAK74096 Human high bone ma
C 42	201.6	5.6	54108	24	ABK22782 Human HbM gene reg
C 43	201.6	5.6	57273	22	ABK22782 Human HbM gene reg
C 44	201.6	5.6	66933	24	ABK22782 Human HbM gene reg
C 45	201.6	5.6	72049	22	ABA82623 Human HbM gene reg

ALIGNMENTS

RESULT 1	AAK93601	standard; cDNA; 5099 BP.
ID	AAK93601	
AC	AAK93601	
XX		
XX		
DT	07-MAY-1998	(first entry)
DE	Human eosinophil ectaxin receptor CC CKR3 encoding cDNA.	
XX		
XX		
KW	Eosinophil ectaxin receptor; CC CKR3; human; treatment: dermatitis; atopic condition; allergic rhinitis; conjunctivitis; bronchial asthma; beta-chemokine receptor; viral infection; ss.	
KW		
XX		
OS	Homo sapiens.	
XX		
FH		
FT	Key	Location/Qualifiers
FT	misc-feature	1..3586
FT		/tag= a
FT		/note= "5' genomic DNA flanking sequence"
FT	CDS	3587..4654
FT		/tag= b
FT		/product= "human eosinophil ectaxin receptor"
FT	misc-feature	4655..5099
FT		/tag= c
FT		/note= "terminator region"
PN	MO9741154-A1.	
XX		
PD	06-NOV-1997.	
XX		
PF	24-APR-1997;	97WO-US06568.

XX 17-JAN-1997; 97GB-0000894.
PR 26-APR-1996; 96US-0016158.
PR 26-APR-1996; 96US-0017113.
XX
XX (MERI) MERCK & CO INC.
PI Daugherty BL, Demartino JA, Siciliano SJ, Springer MS;
XX WPI; 1997-549685/50.
DR P-PSDB; AAW31850.
XX
PT New isolated human eosinophil ectaxin receptor - used to develop
PT products for treating and preventing atopic conditions e.g. allergic
PT rhinitis, dermatitis, conjunctivitis and bronchial asthma
XX
XX
PS Claims 12, 13, 14; Pages 16-20; 51pp; English.
XX
CC This cDNA encodes a human eosinophil ectaxin receptor. This 5099 base
CC pair sequence comprises a 1065 base pair open reading frame encoding a
CC 355 amino acid eosinophil ectaxin receptor protein, flanked by a 5'
CC genomic DNA sequence and a 3' terminator region. This novel eosinophil
CC ectaxin receptor is a human beta-chemokine receptor designated CC CKR3.
CC Agents which bind to this eosinophil ectaxin receptor can be used for
CC the treatment and prevention of atopic conditions such as allergic
CC rhinitis, dermatitis, conjunctivitis and bronchial asthma. Agents which
CC block this eosinophil ectaxin receptor can be used to prevent viral
CC infection in healthy individuals and slow or halt viral progression
CC in infected patients.
XX
SQ Sequence 5099 BP; 1388 A; 1171 C; 1013 G; 1527 T; 0 other:

Query Match 100.0%; Score 3586; DB 18; Length 5099;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 3586; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GGAATCCCTACTCTCCCATCAGAGCTAGGGGCGATGGAGCGCTCTGCTAAGATGGGGA 60
DB 1 GGAATCCCTACTCTCCCATCAGAGCTAGGGGCGATGGAGCGCTCTGCTAAGATGGGGA 60
QY 61 CCCCCAAGAAATGCTCCTGTGGGGCACTTCTTACAGATGGGAGGGGCGGCTT 120
DB 61 CCCCCAAGAAATGCTCCTGTGGGGCACTTCTTACAGATGGGAGGGGCGGCTT 120
QY 121 AAGTGTGTGTCAGGCGAGAAAAAAGATCTAGTTTGTACTCTTGAGAGTTCTCGGTTT 180
DB 121 AAGTGTGTGTCAGGCGAGAAAAAAGATCTAGTTTGTACTCTTGAGAGTTCTCGGTTT 180
QY 181 GTTCATGCGCATGGGCGAGGAGTCAAGAGACAGCCTTCCCTCAGTCCCTACAGTGCA 240
DB 181 GTTCATGCGCATGGGCGAGGAGTCAAGAGACAGCCTTCCCTCAGTCCCTACAGTGCA 240
QY 241 GGAAGAGTGCATAGCCTGGGCGAGGCGCAGGCGCTGTGTGAGGCGCTAGTGGTAACA 300
DB 241 GGAAGAGTGCATAGCCTGGGCGAGGCGCAGGCGCTGTGTGAGGCGCTAGTGGTAACA 300
QY 301 GAGGCGCTCTCAATTCAGCCCAAGAAAGACTAAGATGAATACCTCTGAGTATTATGAC 360
DB 301 GAGGCGCTCTCAATTCAGCCCAAGAAAGACTAAGATGAATACCTCTGAGTATTATGAC 360
QY 361 TACAACCCACACAGACAGGTTTCCAGAAAAAGGCTCAGCGTTGGAAACCAAGGTCAAC 420
DB 361 TACAACCCACACAGACAGGTTTCCAGAAAAAGGCTCAGCGTTGGAAACCAAGGTCAAC 420
QY 421 TCAGACGACACCAAGTCTATTAATCAAGAGACAAACAGAGACAGGAGACACCCCTTCCA 480
DB 421 TCAGACGACACCAAGTCTATTAATCAAGAGACAAACAGAGACAGGAGACACCCCTTCCA 480
QY 481 CTCTGCCCATGTCCTCAAGTTGTAGTGCCCTTCTCAGATCTCTGCCACCAATCTTGA 540
DB 481 CTCTGCCCATGTCCTCAAGTTGTAGTGCCCTTCTCAGATCTCTGCCACCAATCTTGA 540
QY 541 AAGGAACACTGAAGAAAGAACTGAATTTATTAAGCTGACAGCATTAAGAGGATGAGTAA 600

DB 541 AAGGAACACTGAAGAAAGAACTGAATTTATTAAGCTGACAGCATTAAGAGGATGAGTAA 600
QY 601 ACCATAATCATTTGTTCACATGSAATGAATCAAGAGAAAGTTAAACCACTTGGACATAAA 660
DB 601 ACCATAATCATTTGTTCACATGSAATGAATCAAGAGAAAGTTAAACCACTTGGACATAAA 660
QY 661 TGTGTGAATCCTTTTCCCTGCTATCCAGCAGATGAGAGAGCTGGTAACAGACACAAAT 720
DB 661 TGTGTGAATCCTTTTCCCTGCTATCCAGCAGATGAGAGAGCTGGTAACAGACACAAAT 720
QY 721 GTTTGGAGACTAAAGAAATCATTTGCATTTTCTGCTGACTGTCTATTTGAGTAAATTTA 780
DB 721 GTTTGGAGACTAAAGAAATCATTTGCATTTTCTGCTGACTGTCTATTTGAGTAAATTTA 780
QY 781 GTTGACCTCCTTTGTAATCAATCTGACAGGGGCAATCCAAATTCGCAACAAAGATAG 840
DB 781 GTTGACCTCCTTTGTAATCAATCTGACAGGGGCAATCCAAATTCGCAACAAAGATAG 840
QY 841 TTAAACAGTGTAAATGCTGCATGAGAGATTTGGTGAATTTTACTTTTCTTTTGTGCT 900
DB 841 TTAAACAGTGTAAATGCTGCATGAGAGATTTGGTGAATTTTACTTTTCTTTTGTGCT 900
QY 901 CTTCCTTTCTTATTTGTTCTTACTTATTTAGATTAACCTATCGTTTCCAAATGTAAA 960
DB 901 CTTCCTTTCTTATTTGTTCTTACTTATTTAGATTAACCTATCGTTTCCAAATGTAAA 960
QY 961 GGGCATTTTGAAGCCATATTCAAACCTCTTCACTATTTGTAATGATATTCACCTTG 1020
DB 961 GGGCATTTTGAAGCCATATTCAAACCTCTTCACTATTTGTAATGATATTCACCTTG 1020
QY 1021 ATTGAGACTGGTAGACAGGTGAAACCATATCAGGTTTAAATTTTAAATTTTAAAT 1080
DB 1021 ATTGAGACTGGTAGACAGGTGAAACCATATCAGGTTTAAATTTTAAATTTTAAAT 1080
QY 1081 ATTTATTTATTTATTTATTTTGGAGATGAGTCTGCTGCTGCCAGCGCTGAGTGCA 1140
DB 1081 ATTTATTTATTTATTTATTTTGGAGATGAGTCTGCTGCTGCCAGCGCTGAGTGCA 1140
QY 1141 CGGGGTATACAGATTCACGACGACCTTCATAGCTTCAAGGAAATTCGCCACCTC 1200
DB 1141 CGGGGTATACAGATTCACGACGACCTTCATAGCTTCAAGGAAATTCGCCACCTC 1200
QY 1201 AGCCCCCAAGTAGTTGGGCGACACAGTATGCGCAACATGCTGCTGCTTCTTATTT 1260
DB 1201 AGCCCCCAAGTAGTTGGGCGACACAGTATGCGCAACATGCTGCTGCTTCTTATTT 1260
QY 1261 TTTTGTGAGATAGATCTACTATATTTGTCAGGCTGGTCTTGAATTCCTGGGCTCAG 1320
DB 1261 TTTTGTGAGATAGATCTACTATATTTGTCAGGCTGGTCTTGAATTCCTGGGCTCAG 1320
QY 1321 TGAGCCCTCCACCTGGGCGCTCCCAAGTACTGGGATTTACAGGATGAGCCAGAGTCCCT 1380
DB 1321 TGAGCCCTCCACCTGGGCGCTCCCAAGTACTGGGATTTACAGGATGAGCCAGAGTCCCT 1380
QY 1381 GCCCATATGAGATTTTCTGCTCTGATCCCATGACAGCTAGTAATCAAGACTTGGCTGCT 1440
DB 1381 GCCCATATGAGATTTTCTGCTCTGATCCCATGACAGCTAGTAATCAAGACTTGGCTGCT 1440
QY 1441 GACTCTGAGAGAGCTGATCTTCTTTGAGCTGTGAACCTTCAATGCTCAATAG 1500
DB 1441 GACTCTGAGAGAGCTGATCTTCTTTGAGCTGTGAACCTTCAATGCTCAATAG 1500
QY 1501 CAGCCCTGAAACCCAAACCAAGGTTCTATGGTTATCATCTCTGATCATGTTGATTTTA 1560
DB 1501 CAGCCCTGAAACCCAAACCAAGGTTCTATGGTTATCATCTCTGATCATGTTGATTTTA 1560
QY 1561 TAGAAATTAACATGAATTTAAAGACATACCTCAACTGAGCAAAATTAAGTAAATTTT 1620
DB 1561 TAGAAATTAACATGAATTTAAAGACATACCTCAACTGAGCAAAATTAAGTAAATTTT 1620
QY 1621 TTTTAAAGTTTGAACCTGTTTAAATCACTCTTGAGAAAAAGAAATTAATTAATTA 1680
DB 1621 TTTTAAAGTTTGAACCTGTTTAAATCACTCTTGAGAAAAAGAAATTAATTAATTA 1680

Db 1621 TTTAAAGTTGACCTGTTTAAATCACTCTTGAGAAAAAGAAAATAATACAAATA 1680
Qy 1681 TTAACGGTAATACAGAGCTACTATACCTTTGTTCTCCAGAAATTAGACAGTTCTGTTCTTTT 1740
Db 1681 TTAACGGTAATACAGAGCTACTATACCTTTGTTCTCCAGAAATTAGACAGTTCTGTTCTTTT 1740
Qy 1741 CTTCCTTTAGATGCTGAAGTGCAGAAAGACACTCTGTGATTTAGCTGTGTAACAGACA 1800
Db 1741 CTTCCTTTAGATGCTGAAGTGCAGAAAGACACTCTGTGATTTAGCTGTGTAACAGACA 1800
Qy 1801 AATGATATTTTTTTTCTCAGCTGCTATGAGATTTGATTTATGATTTATTAATAAGATGC 1860
Db 1801 AATGATATTTTTTTTCTCAGCTGCTATGAGATTTGATTTATGATTTATTAATAAGATGC 1860
Qy 1861 TGATGGAGACACACAAACATTTGTTCTCAGTCCATTTTCTCCTCAAAAGCCGTGA 1920
Db 1861 TGATGGAGACACACAAACATTTGTTCTCAGTCCATTTTCTCCTCAAAAGCCGTGA 1920
Qy 1921 ATGTGCCATTGATCAGTGGAGATGTACCTGAGACAGACCCATGAAAAGATCAACAGT 1980
Db 1921 ATGTGCCATTGATCAGTGGAGATGTACCTGAGACAGACCCATGAAAAGATCAACAGT 1980
Qy 1981 TCCACCCCAAGGACCCCTATTTTCTCAATTTTCAATTTGAAATGGCTTTCTATTTGCTCT 2040
Db 1981 TCCACCCCAAGGACCCCTATTTTCTCAATTTTCAATTTGAAATGGCTTTCTATTTGCTCT 2040
Qy 2041 TTCAATTCCTGCTTCCACAGTTTACAGCTTTTCTGTTTCAATGTAATGTAACATATA 2100
Db 2041 TTCAATTCCTGCTTCCACAGTTTACAGCTTTTCTGTTTCAATGTAATGTAACATATA 2100
Qy 2101 CACTCTCATTTTTCTCATCAGACCCCAAGTACCCCAATGTTCTCTCACTTTGATATTA 2160
Db 2101 CACTCTCATTTTTCTCATCAGACCCCAAGTACCCCAATGTTCTCTCACTTTGATATTA 2160
Qy 2161 GTAAAGAGAGCTCTGATTAAGAGCTGTGCAAGCAGCAGCTGAGAGCCCTAGAGACT 2220
Db 2161 GTAAAGAGAGCTCTGATTAAGAGCTGTGCAAGCAGCAGCTGAGAGCCCTAGAGACT 2220
Qy 2221 GGCTCCATTTCCATCTCTATTTCTCACTGACTGACTACCAAGACCCCAATGAGGAG 2280
Db 2221 GGCTCCATTTCCATCTCTATTTCTCACTGACTGACTACCAAGACCCCAATGAGGAG 2280
Qy 2281 CCTCAGTATGATCAATTAATTTAAAGACAAAACAATTCCTCCGATTTGGCCCCA 2340
Db 2281 CCTCAGTATGATCAATTAATTTAAAGACAAAACAATTCCTCCGATTTGGCCCCA 2340
Qy 2341 GTTATTAAGCATTTCTCAGATTTACCTTGAGAAATGCCATGGGCTGTATTTACATC 2400
Db 2341 GTTATTAAGCATTTCTCAGATTTACCTTGAGAAATGCCATGGGCTGTATTTACATC 2400
Qy 2401 TTACACCTTTGCTCTCTCCTAGAAAGAGAAAGTCACTTGATGGCCCTGAGAGACT 2460
Db 2401 TTACACCTTTGCTCTCTCCTAGAAAGAGAAAGTCACTTGATGGCCCTGAGAGACT 2460
Qy 2461 AGTGCATGGCTTAAGTCTCTCCTAGAAAGAGAAAGTCACTTGATGGCCCTGAGAGACT 2520
Db 2461 AGTGCATGGCTTAAGTCTCTCCTAGAAAGAGAAAGTCACTTGATGGCCCTGAGAGACT 2520
Qy 2521 TTTTCCACGCAAGTCTATATATCTCAAGAAAGAGAGCAGCTGAGGCTTCTGAGCTTA 2580
Db 2521 TTTTCCACGCAAGTCTATATATCTCAAGAAAGAGAGCAGCTGAGGCTTCTGAGCTTA 2580
Qy 2581 AGAATATCAAGTCTAGAGAAATCCATTTAGTACGACCCCTGCTTACCCCTTTGTG 2640
Db 2581 AGAATATCAAGTCTAGAGAAATCCATTTAGTACGACCCCTGCTTACCCCTTTGTG 2640
Qy 2641 ATGAGAAAGCTCCAGGGGTTTGTGATTTGATTTACAGGCTTAACCTCAGATCACA 2700
Db 2641 ATGAGAAAGCTCCAGGGGTTTGTGATTTGATTTACAGGCTTAACCTCAGATCACA 2700
Qy 2701 GGGGGAAGAAAGAAAGTAACTAACTAACTAACTAACTAACTAACTAACTAACTAACTAA 2760
Db 2701 GGGGGAAGAAAGAAAGTAACTAACTAACTAACTAACTAACTAACTAACTAACTAACTAA 2760

Qy 2761 GTTAATTAAGTATGATTTGATGATGTAACAGACAAATGATTTTTCACAGCTGCT 2820
Db 2761 GTTAATTAAGTATGATTTGATGATGTAACAGACAAATGATTTTTCACAGCTGCT 2820
Qy 2821 GTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTG 2880
Db 2821 GTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTGATTTG 2880
Qy 2881 TCAAGTCCCTACCAATTTTTCAAAAGTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTT 2940
Db 2881 TCAAGTCCCTACCAATTTTTCAAAAGTTAAATTTTAAATTTTAAATTTTAAATTTTAAATTT 2940
Qy 2941 GACAGAGAAATGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 3000
Db 2941 GACAGAGAAATGACATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 3000
Qy 3001 TTAGAGATTTTGAACAAATTTCTAAATTTCTCAAGTTCAATTTCCCATTAACATATA 3060
Db 3001 TTAGAGATTTTGAACAAATTTCTAAATTTCTCAAGTTCAATTTCCCATTAACATATA 3060
Qy 3061 ATGATGCTCTCATTTATGAGGCTTGAAGAGATTAATTTACTTTGATTTGATTTGATTTG 3120
Db 3061 ATGATGCTCTCATTTATGAGGCTTGAAGAGATTAATTTACTTTGATTTGATTTGATTTG 3120
Qy 3121 ATTTGATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTT 3180
Db 3121 ATTTGATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTT 3180
Qy 3181 TAACTGTAAACATTAATTAATGCAAAATGCGTAAAGAGACAGTAAATTAATTAATTAATTA 3240
Db 3181 TAACTGTAAACATTAATTAATGCAAAATGCGTAAAGAGACAGTAAATTAATTAATTAATTA 3240
Qy 3241 TATATTTGATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTT 3300
Db 3241 TATATTTGATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTTATTT 3300
Qy 3301 TACAGAAATCTGATTTCCCATTTCTCACCACACCCCAACATTTGCTTTTCC 3360
Db 3301 TACAGAAATCTGATTTCCCATTTCTCACCACACCCCAACATTTGCTTTTCC 3360
Qy 3361 ATGCGGTCATCTAATTTGAAGCTTCAAGCTTTCTCTCAATCTCTCTGCG 3420
Db 3361 ATGCGGTCATCTAATTTGAAGCTTCAAGCTTTCTCTCAATCTCTCTGCG 3420
Qy 3421 ACCCTGATATGCTTTTGAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCA 3480
Db 3421 ACCCTGATATGCTTTTGAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCAATTTCA 3480
Qy 3481 CATCTTTGATGATCAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 3540
Db 3481 CATCTTTGATGATCAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 3540
Qy 3541 CATTTGGGATTTGATTTTCTTTCTTATACAGAGGAGAACTGAA 3586
Db 3541 CATTTGGGATTTGATTTTCTTTCTTATACAGAGGAGAACTGAA 3586

RESULT 2
ABLJ32337/c
ID ABLJ32337 standard: DNA: 7201 BP.
XX ABLJ32337;
AC
AC 26-MAR-2002 (first entry)
XX
XX Human immune system associated gene SEQ ID NO: 310.
DE
XX Human immune system associated gene SEQ ID NO: 310.
XX
XX Human: immune system disease: cytosine methylation; antileukemic;
KW antileukemic; antileukemic; antileukemic; antileukemic;
KW antileukemic; antileukemic; antileukemic; antileukemic;
KW antileukemic; antileukemic; antileukemic; antileukemic;
KW antileukemic; antileukemic; antileukemic; antileukemic;
KW antileukemic; antileukemic; antileukemic; antileukemic;

KM	acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KM	neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KM	gene; ds.
XX	
OS	Homo sapiens.
XX	
PN	WO200200928-A2.
XX	
PD	03-JAN-2002.
XX	
PF	02-JUL-2001; 2001WO-EP07537.
XX	
PR	30-JUN-2000; 2000DE-1032529.
PR	01-SEP-2000; 2000DE-1043826.
XX	
PA	(EPIC-) EPICENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
DR	WPI; 2002-130909/17.
XX	
PT	Nucleic acid comprising fragment of chemically modified gene, useful
PT	for diagnosis and treatment of diseases associated with abnormal
PT	cytosine methylation -
XX	
PS	Claim 1; SEQ ID NO 310; 32pp + Sequence Listing; German.

CC The present invention provides a number of human immune system associated
CC genes which are modified by the methylation of cytosines. The sequences
CC can be used in the diagnosis and treatment of immune system disorders,
CC including eye diseases such as retinopathy, neovascular glaucoma and
CC macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC diseases. The present sequence is a gene of the invention.
xx
SQ Sequence 7201 BP; 2131 A; 65 C; 1603 G; 3402 T; 0 other;

	Query Match	Best Local Similarity	Score	DB	Length
Matches 2889; Conservative	67.1%;	80.6%;	2406;	24;	7201;
	Pred. No. 0;	Mismatches 685;	Indels 12;	Gaps 6	

QY	3	ATCCCTACCTTCCCATCAGACGTAGGGGCGATGAGCGCCTCTTCGTATAGTGGGAC	62
Db	5746	ATCCCTACCTTCCCATCAGACGTAGGGGCGATGAGCGCCTCTTCGTATAGTGGGAC	5687
QY	63	CCCAAGGAATGTCCCTGTGGGGCACTTCCTTACCAGATGGGAGCGAGCGGTAA	122
Db	5686	CCCAAAAAATGTCCCTGT - AAACACTTCCTTACCAGATTAATAATACCATACATTTA	5628
QY	123	GTGGTGTCAGGACGAAAAAAGATCTAGTTGTACTCTTGACAGTTCTCGGTTGT	182
Db	5627	ATTATATATCAACAAAAAATAATCTATTTATACCTTAAAAATTCCTCGATTAT	5568
QY	183	TCATAGGCGTGGGCGAGGAGTCAAGGAGCGAGACCTTGCTCAGTGCCATACAGTGCAGG	242
Db	5567	TCATATACCTTAACAAAAATCTAAAAACAACACTTACCTCTAATACCTCAACATACAA	5508
QY	243	AAAAAGTCATAGCCTGGGCGAGGCGCCCTGTGGAGCGCTAGTGTTAACAGAGA	302
Db	5507	AAAAATATCATTAACCTTAAGC - - - GCGAAAAACCTTAATAAAAAAGTAATTAATACAAAA	5451
QY	303	GGGCTCTGCATTTCCAGGCCCAAGGAAGACTAAGATTAATTAATCTCATGAGTATATTAGCTA	362
Db	5450	AAACCTCTCATTTCCACCCAAAAAATCTAAATTAATTAATTAATTAATTAATTAATTA	5391
QY	363	CAAAACACACAGAGGTTCCAGAAAAAGGCTCAGGTTGGAACAGGCAACCCCACTC	422
Db	5390	CAAAACACACAAATAATTTCCAAAAAATAAACTCAAGCTTAAACCAATCAACCCCACTC	5331
QY	423	AGCAGACACAGTATATTAATCAAGGACCAACAGSAGACAGAAACACCCCTTCCACT	482
Db	5330	AACAAACACAGTATATTAATCAAAACACACAAAAAACAACCCCTTCCACT	5271

Qy	483	CTGCCCATGTCCTCAAGTGTGTAGTGGCCCTCTCTCCAGATCTCTCGCAACATCTTAGAA	542
Db	5270	CTACCCCATATCTCAAAATTAATTAATACCCCTCTCTCCAAATCTCTACACCACTTTAA	5211
Qy	543	GGAACACAGAAAGAGAACTGAAATTAATAGCTGACACATAAAGAGATGAGTAANAC	602
Db	5210	AAACACTAAAAAANAANAATAATTAATTAATCTAGCAACATTAANAANAATAATTAANAC	5151
Qy	603	CTAAATCATTTGTTCACATGAATGAATCAAGAGAGTTAAACCACTTTGGACTPAATG	662
Db	5150	CTAAATCATTTGTTCAATTAATTAATTAATCAAAAAAATTTAAACCACTTTAACTAAATA	5091
Qy	663	TGTGAATCCCTTTCCAGATCCAGAGATGGAAGTGGAATGAGAGACCACTAGT	722
Db	5090	TATATATCTTTTCTGACTATCTCAACAAATTAANAACATTAATTAACAANAACCAAAATAT	5031
Qy	723	TTGGAGACTAAAGATATTTGCACATTTCACTGCTAGTTGATTTGTAGTAATTTTGT	782
Db	5030	TTAAATACTAAANAATCATTAACATTTTCACTACTTAATTAATTAATTAATTAATTTTAT	4971
Qy	783	TGACCTAC-TTTGTAATCTTGACACGGGGCAATCAATATCTGCACAGAGATANGT	841
Db	4970	TAACTCATTTTAAATATCTACACAG- ---AACATCACTATCTACACAAAATATA	4916
Qy	842	TAAACAGGTAATTCGTGCATGAGAGATGGGTGATTTTACTGTTTGTGCTC	901
Db	4915	TTTAACAATTAATTAATCTACTACATTAANAATAATTAATTAATTTTACTTGCTTTTAACTC	4856
Qy	902	TTCTTTCTTAATTTGTCCTACTTAATTAACATTAACCTATGCTTTTCCAAAATGAAGA	961
Db	4855	TTCTTTCTTAATTTCTTACTTAATTAACGATTAACCTATGCTTTTCCAAAATGAAGA	4797
Qy	962	GCATTTTGAAGGCTATTTCAAAACCCCTCACTATTTTGTATGAAGATTCACCTTGA	1021
Db	4796	ACCATTTTAAAAACCTATTTCAAAACCTTCACTATTTTATATCTAAATATTCACCTTAA	4737
Qy	1022	TTGAGACTGGGTAGACAGTGAAAAACCAATACAGTTTTTAATTTTTTAATTAATTA	1081
Db	4736	TTAAACATTAATTAACAANAATAAACAACCAATTAATTTTAATTTTAATTTTAATTA	4677
Qy	1082	TTTATTTTATTTATTTTTTTGGATGAGGTGGCTGTGCGCCAGGCTGAGAGCGAC	1141
Db	4676	TTTATTTTATTTATTTTATTTTAAAAAATCTAACTATTCGCCAACAATAAATTAACAC	4617
Qy	1142	GGCGTATCACAGTTCACGTGAGGCTCAACCTTCTAGGCTCAAGGATTTCTCCACCTCA	1201
Db	4616	GACGTATACAAATTCACCTCAACCTCAACCTTCTTAACGTCAAAAATTTCTCCACCTCA	4557
Qy	1202	GGCCCCAAGTAGTTGGGACACACGTATGCGCCACCATGCTGGCTAATTTCTTATTTT	1261
Db	4556	AACCCCAAAATTAATTAACAACACACGTATAGCGACACCATACCTAACTAATTTCTTATTTT	4497
Qy	1262	TTTGTAGATGAGATGCTCACTATATATGTCAGAGGTGCTGGAATTCCTGGGCTCAGT	1321
Db	4496	TTTATTAATAATTAATATCTCACTATATTAATTCACAACTATATCTTAAATTCCTAACTCAAT	4437
Qy	1322	GAGCTCCACCTGGGCTCCCAAGTAGTGGGATTACAGCATGAAGCAAGTCCCGCTG	1381
Db	4436	AAACCTCCACCTAAACCTCCCAAAATTAATTAACAACATTAACCAAAATTCCTCA	4377
Qy	1382	CCCATATTAATTTTCTATCTCTATCCATACATTAATTAATCAAAAACCTTAACCTACTA	4317
Db	4376	CCCATATTAATTTTCTATCTCTATCCATACATTAATTAATTAATTAATTAATTAATTA	4317
Qy	1442	ACTGTGAGAGCTCAAGTGTCTTCTTGAGCTGGAATCTAGTCAAAAAGCTCATAGGC	1501
Db	4316	ACTGTAAAAAAGCTAACATCTTCTTAACATTAANAACCTCAATACATAAAGCTCAATAC	4257
Qy	1502	AGCCTGAACCCAAACCAAGGTTCTATAGTTTATCATCTGATCATGTTGATTTAT	1561
Db	4256	AACCTTAACCCAAACCAAAATTTCTATATTTTATATCTCCGAGCATTAATTAATTTAT	4197

OY	1562	AGAAATTAACACATGATTAATAAGCACTACCCCTCAACACTGAGCAAAACCTTAAGTAATTTT	1621
OY	1562	AA	1621
Db	4196	AAAAATTAACACATTAATAATAAAAACTACCCCTCAACACTAAACAAACCTTAATAATAATTTT	4137
OY	1622	TTAAAGTTTGACCGTTTAAATCACTCTGGAGAAAAAGAAATTAATTAACAATTAAT	1681
Db	4136	TTTAAATTTTAACTATTTTTAAATCACTCTTAAAAAAAAAAAAAAAAAAAAAAAAAATAATCAATATAT	4077
OY	1682	TAAAGGTGAATACAGCTACTATACCTTTGTCTCCAGATTAATAGCATTTGTCTGTCTTC	1741
Db	4076	TAAAGGTGAATACAGCACTACTATACCTTTTATCTTCCAAATTAATTAACAATTTCTATTCTTTTC	4017
OY	1742	TTGCTTATAGATGCTGAAGTGCAGAGACACTGTGATTTGACGTGTGAATCAGCAAA	1801
Db	4016	TTACTTAAATTAATTAATAATAATAAAAAAACTCTATAAATTAATCAATATAATCAACAAA	3957
OY	1802	ATGCTATATTTTTCCTCAGCTGCTATGAGTTGGATTAATGATTAATGAATAGAAATGCT	1861
Db	3956	ATATATATTTTTCCTCAGCTGCTATGAGTTGGATTAATGATTAATGAATAGAAATGCT	3897
OY	1862	GATGGAGACACACAAACCAATTTGTTCCTCAGCTGCTATTTCTCTCTCAAAAGCTGGAA	1921
Db	3896	AAATAAACACACACAAACCAATTTATTCCTCAATTCATTTCTCTCTCAAAACCTTAAA	3837
OY	1922	TGTGCAATGATCAGTGGAGATGTACTGGACAGACCCATGAAGAGATCAACAAGT	1981
Db	3836	TATACCTTATTAATCAATTAATAATAATAATAATAATAATAATAATAATAATAATAATAAT	3777
OY	1982	CCACCAAGGAGACCCCTTTTCTCTAATTTCAATTTGAATTTGCTCTCTAATTTCTCTCT	2041
Db	3776	CCACCAAGGAGACCCCTTTTCTCTAATTTCAATTTGAATTTGCTCTCTAATTTCTCTCT	3717
OY	2042	TCATTTCTGCTTCCCTACAGTTTTCAGCTTTTTCGTGTTTCAATTTGAATTCACATAC	2101
Db	3716	TCATTTCTGCTTCCCTACAGTTTTCAGCTTTTTCGTGTTTCAATTTGAATTTGAATTCACATAC	3657
OY	2102	ACTCTCATTTTCTCTATACAAACCCCAAGTGACCCCAATGCTCTCCTCTGATTAATAG	2161
Db	3656	ACTCTCATTTTCTCTATACAAACCCCAATTAACCCCAATTAACCCCAATTAACCCCAATTAAT	3597
OY	2162	TAAAGGAGGCTCTGATTAAGGGCTGTCCAGACGACGAGCTGGAGGGCTGAGAGCTG	2221
Db	3596	TAAAGGAGGCTCTGATTAAGGGCTGTCCAGACGACGAGCTGGAGGGCTGAGAGCTGAGAGCTG	3537
OY	2222	GCTCCATTTCCATCTCATTTCTCAGTACGCTTGTACACCAACCCCAATGAGGGG	2281
Db	3536	ACTCATTTTCCATCTCATTTCTCAGTACGCTTGTACACCAACCCCAATGAGGGG	3477
OY	2282	CTCAGTATTTGATCAATTAATTTTAAGAAGCAAAACCAATTTCCCGGATGAGCCGAG	2341
Db	3476	CTCAGTATTTGATCAATTAATTTTAAGAAGCAAAACCAATTTCCCGGATGAGCCGAG	3417
OY	2342	TTATTAAGCATTTCTCAGATTTTACCTTGAGAAATGGCCATGGGCTGTATATTCAATCT	2401
Db	3416	TTATTAAGCATTTCTCAGATTTTACCTTGAGAAATGGCCATGGGCTGTATATTCAATCT	3357
OY	2402	TCACCTTTGCTCTCTCTCTCCTAGAAAGAGAAAGTCAGTGGATGGGCTCTGAGAACTA	2461
Db	3356	TCACCTTTGCT	3297
OY	2462	GTCGATGGCTTAACCTGTCTCTGATGATGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT	2521
Db	3296	ATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT	3237
OY	2522	TTTCAACCGAAGTCTATATATCTCAAGAAAGCAGGACCTGGCTTATAGGCTCTCTGGCTTAA	2581
Db	3236	TTTCAACCGAAGTCTATATATCTCAAGAAAGCAGGACCTGGCTTATAGGCTTATAGGCTTAA	3177
OY	2582	GAAATATCAATCACTGAGGAGAAATCCCATTTGATGATGACCCCTCTGTGTTACCCCTTTGGA	2641
Db	3176	AAATATCAATCAATCAATCAATCAATCAATCAATCAATCAATCAATCAATCAATCAATCAAT	3117
OY	2642	TGGAGAACCTCCAGGGGTTTGTCTTTTGTGATGTTACAGGCTTAATCAGCATACAG	2701

Db	3116	TTAAAAACCTCCAAAAATTACTCTTTTACATATTTACCAACCTAACCTACATCTACCA	3057
Qy	2702	GGCGACGAAGAAGTAAGTAACCTAACCTAATGCTGCTTAATTTGAATTTATTTGAATG	2761
Db	3036	AAACAAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA	2997
Qy	2752	TTAATTTACTGTATGTAGCATGTGTGTAAACAGACAAAAATGTATTTTTTTCACAGCTGCTG	2821
Db	2996	TTAATTTACTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA	2937
Qy	2822	TGATTTGGATTTATCCCATTTTGGATTAAGAATGCTGTTAAGAGACACAAAGCAGTTCCT	2881
Db	2936	TAAATTAATTAATTTATCCATTTTAAATTAATTAATTAATTAATTAATTAATTAATTA	2877
Qy	2882	CAAGCCGTACCAAAATTTTTCACAAAGTTAAATTTAAATAATTCACATTTTGAATCTAGTG	2941
Db	2876	CAATCCGTACCAAAATTTTTCACAAATTTTAAATTTTAAATAATTCACATTTTGAATCTA	2817
Qy	2942	ACAGAGAAATGAGCATGATAGAGACTAAAGATCTAGCCCAATTTTATATTTACTTGT	3001
Db	2816	ACAAAAAATAAATCAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT	2757
Qy	3002	TAGAGATTTTGAACAAATTTCTAATAATTTCTTAAGCTTCAATTTCCCATTAACATAA	3061
Db	2756	TAAAAAATTTTAAACAAATTAACATAATTTCTTCAAAATTTCAATTTCCCATTAACATAA	2697
Qy	3062	TGAATGCTCATCATTTTGGGCGCTGAGAACCATTAATTTACTTGTAAATTTGAATTAATCA	3121
Db	2656	TAAATTAATCTATCATTTTAAACCCCTTAATAAATAACATAATTAATTTATTAATTAATCA	2633
Qy	3122	TTGTTATTTATTTATTTATTCATATTTTGGCTTTTAAATGATTAAGATTTTAAAGTATATGT	3181
Db	2636	TTATTTATTTATTTATTTATTCATATTTTACTTTTAAATTAATTAATTAATTTTAAATATATAT	2577
Qy	3182	AAACTGTAAACATTAATAATGCAAAATGCCGTAAAGACAGTAAATTAATTAATGATTTAT	3241
Db	2576	AAACTGTAAACATTAATAATGCAAAATGCCGTAAAGACAGTAAATTAATTAATGATTTAT	2517
Qy	3242	ATATGTTATATATTAATTCAGAGCTTTTTCCTGTTGCTGTTGATTTTCTCCTTAATAGCT	3301
Db	2516	ATATGTTATATATTAATTCAGAGCTTTTTCCTGTTGCTGTTGATTTTCTCCTTAATAGCT	2457
Qy	3302	ACAGAAATCTGTATCCCATTTCTTCACACACACCCACAAATTTCTGCTTTTCCCA	3361
Db	2456	TCAAAAACTATTAATCCCATTTCTTCACACACCCACAAATTTCTGCTTTTCCCA	2397
Qy	3362	TGCGG-GTCATGCTAATCTTGAAGCTTCAGCTCTTCTCCTCAATCTTCTCCTGCG	3420
Db	2396	TACCAAACTACATTAATCTTGAAGCTTCAGCTCTTCTCCTCAATCTTCTCCTGCG	2337
Qy	3421	ACCTCTGATATGCTTTTGAAGTTCATGTTAAAGATTTCCCTAGCTGATACATGCG	3480
Db	2336	ACCTCTGATATGCTTTTGAAGTTCATGTTAAAGATTTCCCTAGCTGATACATGCG	2277
Qy	3481	CATCTTTTGTAGTACATGAATGAATCAATCACTGCTGTTTTCAGAGATGATTTGCTT	3540
Db	2276	CATCTTTTGTAGTACATGAATGAATCAATCACTGCTGTTTTCAGAGATGATTTGCTT	2217
Qy	3541	CATTTGGGATTTGAATTTTCTTCTCTATCCAGGAGAGATGAA	3586
Db	2216	CATTTGAATTAATTAATTTTCTTCTCTATCCAGGAGAGATGAA	2171
RESULT 3			
ABLJ32336			
ID	ABLJ32336 standard; DNA: 7201 BP.		
XX			
AC	ABLJ32336;		
DT	26-MAR-2002 (first entry)		
XX			
DE	Human immune system associated gene SEQ ID NO: 309.		

XX Human; immune system disease; cytosine methylation; antiasthmatic;
KW antiarteriosclerotic; antianemic; cytosolic; nootropic;
KW neuroprotective; anti-HIV; anticonvulsant; ophthalmological;
KW antirheumatic; antiarthritic; antidiabetic; antipsoriatic;
KW antinflammatory; cancer; eye disease; arteriosclerosis; anaemia;
KW acute myeloid leukaemia; Alzheimer's disease; AIDS; epilepsy;
KW neurofibromatosis; rheumatoid arthritis; psoriasis; bowel disease;
KW gene; ds.
XX
OS Homo sapiens.
PN WO200200928-A2.
PD 03-JAN-2002.
XX
PF 02-JUL-2001; 2001WO-EP07537.
XX
PR 30-JUN-2000; 2000DE-1032529.
PR 01-SEP-2000; 2000DE-1043826.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K:
DR WPI: 2002-130909/17.
XX
PT Nucleic acid comprising fragment of chemically modified gene, useful
PT for diagnosis and treatment of diseases associated with abnormal
PT cytosine methylation
XX
PS Claim 1: SEQ ID NO 309; 32pp + Sequence Listing; German.
XX
CC The present invention provides a number of human immune system associated
CC genes which are modified by the methylation of cytosines. The sequences
CC can be used in the diagnosis and treatment of immune system disorders,
CC including eye diseases such as retinopathy, neovascular glaucoma and
CC macular degeneration, arteriosclerosis, anaemia, cancer, acute myeloid
CC leukaemia, Alzheimer's disease, AIDS, epilepsy, neurofibromatosis,
CC rheumatoid arthritis, psoriasis and inflammatory/ulcerative bowel
CC diseases. The present sequence is a gene of the invention.
XX
SQ Sequence 7201 BP; 2074 A; 65 C; 1393 G; 3669 T; 0 other;
Query Match 63.4%; Score 2271.8; DB 24; Length 7201;
Best Local Similarity 78.2%; Pred. No. 0;
Matches 2805; Conservative 0; Mismatches 772; Indels 10; Gaps 6;
QY 1 GCATCCCTACCTCCCATCAGAGCTAGGGGGGAGCGCTCTGCTAGAGTGGGA 60
DB 1454 GCATTTTATTTTATTTTATTTAGATTAGGGGATGAGCGTTTGTGTTAAGATGGGA 1513
QY 61 CCCCCAAGAAATGTCCTCGTGGGCACCTCTTACAGATGGGATGGCAATGCGGTT 120
DB 1514 TTTTAAAGGAATGTTTTTGTG-GGGTATTTTATTTAGATGGGATGGTATGATGTT 1572
QY 121 AAGTTGGTGTCAGCGAGAAAAAAGATCTAGTTGTACTCTTGAGAGTCTCGGTTT 180
DB 1573 AAGTTGGTGTTAGTGAAGAAAAAAGATTTAGTTGTATTTTGGAGATTTTTCGTTT 1632
QY 181 GTTCATGCGATGGGAGGAGTCAAGAGCAGCGCTTGCCTCAGTGCCTACAGTGA 240
DB 1633 GTTATTCGATGGGTAGGAGTAAAGAGTAAAGTATTTTATTTAGTGTATTAAGTA 1692
QY 241 GGAAGAGTGCATAGCCTGGGCCAAGGCCCTGCTGGAGGGCTAGCTGTAACAGA 300
DB 1693 GGAAGAGTGCATAGCTGGGCCAAGGCCCTGCTGGAGGGCTAGCTGTAACAGA 300
QY 301 GAGGCTCCTCATTCAGCCCAAGGAAGACTAATGATATACCTAGTATGATATAGC 360
DB 1750 GAGGCTTTTATTTATTTAGTTTAAAGAAAGATTAAGAAATATTTATTTATTAAGT 1809
QY 361 TACAAACACACAGCAGGTTCCAGAAAAAGGCTCAGCGTTGGAACAGGTCACCCAC 420

DB 1810 TATAATTTATTTAGTAGTTTAAAGAAAGGTTTAGCGCTTGCAATTTAGTATTTTAT 1869
QY 421 TCAGCAGACACAGCATATTAATCAAGACCAACAGGAGACAGAACCCCTCCCA 480
DB 1870 TTAGTGAATTTAGTATTTAAATTAAGATTAATTAAGGAATTAAGGAATTTTATTTT 1929
QY 481 CTTGCCCCCATCTCCTCAATGTTAGGCGCTTCCCTCCAGATCTCGCCACCATCTTGA 540
DB 1930 TTTTGTATTTATTTTAACTGTAGTGTGTTTATTTTATTTTATTTTATTTTATTTT 1989
QY 541 AAGGAACACTGAAGAAGAACTGAATTTATAGCTGACAGCATTAAGAGATGAGTAA 600
DB 1990 AAGGAATTTGAAGAAAGAAATGAATTTATTAAGTTGATGATTAAGAGATGAGTAA 2049
QY 601 ACCTAAATCATTTGTCATGATGAATGAATCAGAGAGTTTAACCACTTTGACTAAAA 660
DB 2050 ATTTAAATTTATTTGTTTAAATGAATGAATTAAGAGAGTTTAAATTTATTTGATTTAA 2109
QY 661 TGTGTAATCTTTTCTGCTATCCAGCAGATGAGACCTGTTAACAAGACACAATA 720
DB 2110 TGTGTAATTTTATTTTGTATTTAGATGAGAAATTTGTTAATAGATTAATAA 2169
QY 721 GTTGGAGACTAAGAATCATTCACATTTTCACTGCTGAGTTGTATTTGACTAAATTT 780
DB 2170 GTTGGAGATTAAGAAATTTATGATATTTATTTGTTGAGTTGATTTGAGTAAATTT 2229
QY 781 GTTGACCTACCTTTGAAATCTTGACACAGGGGCAATCCAAATCTGCACAAGAGATAG 840
DB 2230 GTTGAATTTATTTTGTAAATTTGTATACGGGATATTTTATTTGT - - ATGAGATAAG 2286
QY 841 TTACAGAGTGTAAATGCTGCATGAGAGATGGGATTTTATTTTACTTCTGTTTGTGCT 900
DB 2287 TTAA-TAGTGTAAATGCTGTATGAGAGATTTGGGATTTTATTTTGTGTTTGTGCT 2345
QY 901 CTTCTTTCTATTTGTTCTTACTATTTAGATTAATCCATATGCTTTCCCAATGTAA 960
DB 2346 TTTTATTTTATTTGTTTATTTATTTATTTAGATTAATTTATGCTTTT-TTAAATGTAA 2404
QY 961 GGCATTTTGAAGACCTAATTCAAACCTCTGCTATTTTGTATCTAAGATTTACCTTG 1020
DB 2405 GGTATTTTGAAGATTAATTTTAAATTTTATTTTATTTTGAATTTAAGTATTTATTT 2464
QY 1021 ATTGAGACTGGTAGACAGCTGAACCATATCAGGTTTATTTTATTTTATTTTATTT 1080
DB 2465 ATTGAGATTTGGGATGATAGTGAATAATTTATTTAGGTTTATTTTATTTTATTT 2524
QY 1081 ATTTATTTATTTATTTATTTTGTAGATGAGTCTGCTGCGCCAGGCTGAGTGCAG 1140
DB 2525 ATTTATTTATTTATTTATTTTGTAGATGAGTCTGCTGCTGTTAGGTTGAGTGTAG 2584
QY 1141 CGCGGTGATCAGATTCATCGACGCTCAACCTTTCAGGCTCAAGGATTTCCCACTC 1200
DB 2585 CGCGGTGATTAAGTATTTATTTATTTTAAATTTTATTTTGAATTTAAGGATTTTATTT 2644
QY 1201 AGCCCCCAAGTAGTGGGACACACAGTATGCGCCACATGCTGGCTGATTTCTTATTT 1260
DB 2645 AGTTTATTAAGTAGTTGGATTAATACGTATGCGCTTATTTATTTTATTTTATTT 2704
QY 1261 TTTTGAAGATAGATCTCCTACTATATTTGTCAGGCTGCTGTAATTTCTGGGCTCAG 1320
DB 2705 TTTTGAAGATAGATCTCCTACTATATTTGTTAGGTTGTTTGAATTTTGGGTTAG 2764
QY 1321 TGAGCTCCCACTGGGCTCCCAAGTCTGAGATTAAGAGCATGAGCAAGTCCCT 1380
DB 2765 TGAGTTTATTTATTTGTTTAAAGTATTTGAGATTAAGGATTAAGTAAAGTATTTT 2824
QY 1381 GCCCATATGAGATTTCTGCTCCTGATCCATGACCTGTATCAAGAGATTTGGTGCT 1440
DB 2825 GTTTATATGAGATTTTGTGTTTATTTATTTATTTATTTATTTATTTATTTATTT 2884
QY 1441 GACTCTGAGAGACCTGATGCTTTCTTGAAGTGTGAATTTCAAGTGTAAAGCTCATAG 1500

Dd 2885 GATTTTGGAGATTTGTATGTTTTTTTGTAGTGTGATTTTGTAGTTAAAGTTATAGG 2944
Oy 1501 CAGCCCTGAACCCAAACCAAGGTTCTATGCTTATCATCCCTCATCGTTGATTTTA 1560
Dd 2945 TAGTTTAAATTTAAATTTAAAGGTTTATGTTTATTTATTTTGCATTAATGTTGATTTTA 3004
Oy 1561 TAGAATTAACACATGAATTTAAAGACATACCCCTCAACAGCAACAACCTTAAGTATTTT 1620
Dd 3005 TAGAATTAATATGCAATTTAAAGATATTTATTTTAAATTTAGCTAAATTTTAAAGTATTTT 3064
Oy 1621 TTTAAAGTTTGACCTGTTTTTAATCACTCTTGAGAAAAGAAATTAATACAAATTA 1680
Dd 3065 TTTAAAGTTTGATTTGTTTTTAAATTTATTTTGGAGAAAAGAAAATTAATTAATTA 3124
Oy 1681 TTAACGGTAATACAGGCTACATACCTTGTCTCCGAATTTACAGATGCTGCTCTTTT 1740
Dd 3125 TTAACGGTAATATAGGTTATATATTTTGTGTTTTTGAATTAATAGTTATGTTTTTTT 3184
Oy 1741 CTTCCTTTAGATGCTGAAGTGAGAGACACACTCTGTGATTGTAGCTGTGAATGACAA 1800
Dd 3185 TTTGTTTAAAGTGTGAAGTGAGAGATATTTGTGATTGTAGCTGTGATTAATGATTA 3244
Oy 1801 AATGTGATTTTTTTTCTCAGCTGTATGATTTGATTAATGCTATTAATGAATTAAGATGC 1860
Dd 3245 AATGTGATTTTTTTTCTCAGCTGTATGATTTGATTAATGCTATTAATGAATTAAGATGC 3304
Oy 1861 TGATGGAGACACACAAACCTTGTCTCCATGTCATTTTCCCTCCCAAGGCTGGA 1920
Dd 3305 TGATGGAGATATATTAATTAATTTGTTTTTGTATTTATTTTTTTTTTAAAGTTTGA 3364
Oy 1921 ATGTGCAATTTGATCATGAGGAGATGTACCTGACAGACCATGAAGAAAGATCAACAAT 1980
Dd 3365 ATGTGTTATGATTTAGTGGAGATGTATTTGATAGATTTATGAAGAAAGATTAATAGT 3424
Oy 1981 TCCACCCAAAGGACCCATTTTTCTCAATTTCAATTTGAATGGCTTCTAATGCTCTCT 2040
Dd 3425 TTTAATTTAAGGATTTTATTTTTTAAATTTTAAATTTGAAATGGTTTTTAAATGTTTTT 3484
Oy 2041 TTTATTTCCGCTCTACACAGTTTAAAGCTTTTCTGTTTCAATGAGATGCACATA 2100
Dd 3485 TTTATTTTTTTTATTTATTTAGTTTATATAGTTTATTTTGTGTTTAAATGGAATTTATTA 3544
Oy 2101 CACTGCTATTTTTCTCATACACACCCCAAGTACCAATGCTCTCACTTTTGCATATTA 2160
Dd 3545 TATTTTTATTTTTTTTATTAATATTTAAGTATTTAATGTTTTTATTTATTTTGCATATTA 3604
Oy 2161 GTAAAGAGAGCTCTGATTAAGGCTTGTCCAAGCAGCAGCTGAGAGCCCTAGAGCT 2220
Dd 3605 GTAAAGAGAGTTTGTATTAAGGTTGTTTAAAGTACCTAGTTGAGAGCCCTAGAGAT 3664
Oy 2221 GGCTCCATTTCCATCTATCTCAGCTGACTGACTACCCAGAAACCCCAATGCGGGS 2280
Dd 3665 GGTTTTATTTTTTATTTTATTTTATGATTTTGAATTTTAAATTTAAATGCGGGS 3724
Oy 2281 CCTCAGTATTTGCATCAATTTCTATTTAAGACAAAACAATTTCCCGCATTTGGCCCCA 2340
Dd 3725 TTTTATGATTTGCATTAATTTATTTAAGAGTAAATAATTTTTCGATTTGGTTTTTA 3784
Oy 2341 GTTATTAAGCATTTCTCAGATTTACCTTGAGAAATGCCATGCGCTGTATATTCACATC 2400
Dd 3785 GTTATTAAGTATTTTATGATTTATTTGAGAAAGTAAATGCTTGTGATTAATTAATTA 3844
Oy 2401 TTTACCCCTTGTCCCTCCCTCCAGAAAGAAAGTCAAGTGCAGTGCCTCTGAGAGACT 2460
Dd 3845 TTTATTTTTTGTTTTTTTTTTGAAGAGAAAGTATGTTGAGATTTTTTTGGAGAAAT 3904
Oy 2461 AGTGATGGCTTAACGTCTTCCATGACTCCCTGCTTATCTGTTTTCTATTTTCCCTCT 2520
Dd 3905 AGTGATGGTTTAATTTGTTTTTTTATGATTTTGTTTATTTGTTTTTATTTTTTTTTT 3964
Oy 2521 TTTTCAACGCAAGTATATATCTCAAGAAAAGCAGCACTGGCCTTAGGGCTCTGGCCTA 2580
Dd 3965 TTTTATCGAAGTTATATATTTTAAAGAAAAGATGATGTTTAAAGGTTTTTGGTTTTA 4024

Oy 2581 AGAATATCAAGTCCAGTGAGAAATCCCATGACTGACCCCTCTGCTTACCCCTTGGG 2640
Dd 4025 AGAATATTAAGTATTAAGTGAGAAATTTTATGATTTGATTTTTTTTGTATTTTTTTG 4084
Oy 2641 ATGAGAAAGCTCCAGGAGGTTTGTCTTGTGATGTTTACAGGCCCTAAGCTACATCACA 2700
Dd 4085 ATGAGAAAGTTTATGAGGTTTGTGTTTGTATGTTAATAGTTAAATTTAGTATTAATA 4144
Oy 2701 GGGGCAAGAAAAGAAAGTAACCTTAACCTATGCTGCTTATTAATTTATTTGTAATA 2760
Dd 4145 GGGGTAAAGAAAAGAAAGTAATTAATTAATGTTTATTAATTTGTAATTTGTAATA 4204
Oy 2761 GTTATTTACTGATTTGATGATGTAAGCAAAAGTGTATTTTTCACAGCTGCT 2820
Dd 4205 GTTATTTATTTGATTTGATGATGTAATGTAATGTAATTAATTTTATTTTATGTTGT 4264
Oy 2821 GTGATTTGATTTATGCCATTTTGGAAATGAAGATGCTTAAGAGACACAGCAGGTTCC 2880
Dd 4265 GTGATTTGATTTATGTTATTTGGAATGAAGATGTTTAAAGATATTAATTTAGTTT 4324
Oy 2881 TCAAGTCCGTACCAATTTTTCAAAAGTTAAATTTAAATTAATCACTACATTTGAATCTAGT 2940
Dd 4325 TTAAGTTCTGATTAATTTTAAAGTTAAATTTAAATTTATTAATTTGAAATTTAGT 4384
Oy 2941 GACAGAGAAATGACATGATAGAGACTAAAGATCTAGCCCAATTTTATTTTACTTG 3000
Dd 4385 GATPAGAGAAATGATATGATAGAGATTAAGATTAATGATTTAAATTTTATTAATTTT 4444
Oy 3001 TTAGAGATTTTGAACAAATTAATCTAAATTTCTCAAGGTTCAATTTCCCATTAATCA 3060
Dd 4445 TTAGAGATTTTGAATTAATTAATTTTAAATTTTAAAGTTTAAATTTTAAATTTAATA 4504
Oy 3061 ATGATGCTCTCATTTATGAGGCCCTGAGAGACATTAATTTACTTTGTAATTTGAATATC 3120
Dd 4505 ATGAAATGTTTATTTATTAAGGCTTTTGGAGAGATTAATTTTGTAAATTTGAATTAAT 4564
Oy 3121 ATTGTTATTAATTAATACATATTTTTCCTTTAAATGATAAGATTTTAAAGTATAG 3180
Dd 4565 ATTGTTATTAATTAATTAATTAATTTTGTGTTTAAATGATAAGATTTTAAAGTATAG 4624
Oy 3181 TTAACGTAAACATTAATAATGCAAAATGCCGTAAAGACAGTAAATTAATTAATTAAT 3240
Dd 4625 TAAATTTGAATTAATAATTAATAATGTAATAATGCTAAAGATTAATTAATTAATTAAT 4684
Oy 3241 TATATTTGTTATTAATTAATTAATTTTGTGTTTAAATGATAAGATTTTAAAGTATAG 3300
Dd 4685 TATATTTGTTATTAATTAATTAATTTTGTGTTTAAATGATAAGATTTTAAATGAT 4744
Oy 3301 TACAGAAATCTGATCCCATCTTCCACACACCCACACACATTTTCTGCTTTCC 3360
Dd 4745 TTTGAAATTTTATTTTATTTTATTTTATTTTATTAATTAATTTTGTGTTTTTTTTT 4804
Oy 3361 ATG-CCGGTACATGAACCTTTGAAGCTTCAGCTCTTCCCTCAATCTCTCTCCCTG 3419
Dd 4805 ATGTCGGGTTATGTTAATTTTGAAGTTTATGTTTTTTTTTTTTTAAATTTTTTTTTT 4864
Oy 3420 CACTCTGATATGCTTTTGAATTCATGTTAAAGATCCCTAGGCTGCTATTCACATGTG 3479
Dd 4865 TATTTTGTATGTTTGTGAAATTTATGTTAAAGATTTTAAAGTGTGTTAATTAATG 4924
Oy 3480 GCATCTTGTGATGATGAATTAATCAATGAGTGTGTTTAAAGAGATTAATGCT 3539
Dd 4925 GTATTTTGTGATGATGAATTAATTAATTTGTTTAAAGAGATTAATGCT 4984
Oy 3540 TCAATTTGGGATTTGATTTTCTTCTTATCAACAGGAGAAATGAA 3586
Dd 4985 TTAATTTGGGATTTGATTTTCTTCTTATTAATTTTAAAGGAGAAATGAA 5031

RESULT 4
AAT85162
ID AAT85162 standard; cDNA: 1915 BP.

```
XX AC AAT85162;
XX DT 14-DEC-1997 (first entry)
XX DE Human chemokine receptor 88-2B cDNA.
XX KW Chemokine receptor 88-2B; atherosclerosis; rheumatoid arthritis;
XX tumor; asthma; viral infection; AIDS; inflammation;
XX autoimmune disease; therapy; diagnosis; leukocyte trafficking;
XX G protein coupled receptor; human; ss.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
XX CDS 362..1429
XX FT /tag= a
XX ET
XX PN WO9722698-A2.
XX PD 26-JUN-1997.
XX PE 20-DEC-1996; 96WO-US20759.
XX PR 07-JUN-1996; 96US-0661393.
XX PR 20-DEC-1995; 95US-0575967.
XX PA (ICOS-) ICOS CORP.
XX PI Gray PW, Raport CJ, Schweickart VL;
XX DR WPI; 1997-341689/31.
XX DR P-PSDB; AAW27124.
XX PT New nucleic acid encoding chemokine receptors 88-2B and 88C - used
XX PT to modulate leukocyte trafficking, e.g. for treatment of
XX PT inflammation, tumours, viral infections, autoimmune diseases, etc.
XX PS Claim 7; Page 48-50; 65pp; English.
XX CC This sequence comprises a full-length cDNA coding for novel human
XX CC chemokine receptor 88-2B (AAW27124), a G protein coupled receptor that
XX CC is involved in leukocyte trafficking. The 88-2B cDNA was obtained
XX CC from a macrophage cDNA library using 88-2B-specific primers. A
XX CC full-length clone (see AAT85161) for chemokine receptor 88C (AAW27123)
XX CC was also obtained. 88C and 88-2B cDNAs can be used to produce
XX CC recombinant polypeptides in transformed host cells for use in the
XX CC treatment of e.g. atherosclerosis, rheumatoid arthritis, tumours,
XX CC asthma, viral infection, AIDS and inflammatory conditions. Nucleic
XX CC acid fragments can be used to isolate genomic sequences, to detect
XX CC alleles of the gene (for diagnosis or in gene therapy), to alter
XX CC receptor genetics to facilitate identification of modulators and to
XX CC produce knockout animals, and (antisense forms) to alter/study the
XX CC genetics and expression of the receptor.
XX SQ Sequence 1915 BP; 488 A; 470 C; 373 G; 584 T; 0 other;

Query Match 9.6%; Score 344.2; DB 18; Length 1915;
Best Local Similarity 98.9%; Pred. No. 4,1e-63;
Matches 357; Conservative 0; Mismatches 3; Indels 1; Gaps 1;
```

```
QY 3406 AATCCTTCTCCTGGACACCTCTGATATGCTTTGAAATTCATGTTAAAGAACCTTAGGC 3465
DB 181 AATCCTTCTCCTGGACACCTCTGATATGCTTTGAAATTCATGTTAAAGAACCTTAGGC 240
QY 3466 TGTATACATATGTCGATCTTTTGTGACATGATTAATTAATCACTGGTGTGTTTACGA 3525
DB 241 TGTATACATATGTCGATCTTTTGTGACATGATTAATTAATCACTGGTGTGTTTACGA 300
QY 3526 AGGATGATTAATGCTTCATGTTGGGATGTAATTTCTCTCTATACACAGGAGAAGTGA 3585
DB 301 AGGATGATTAATGCTTCATGTTGGGATGTAATTTCTCTCTATACACAGGAGAAGTGA 360
QY 3586 A 3586
DB 361 A 361

RESULT 5
ABAI7973/C
ID ABAI7973 standard; DNA; 3660 BP.
XX AC ABAI7973;
XX DT 23-JAN-2002 (first entry)
XX DE Human nervous system related polynucleotide seq ID NO 10304.
XX KW Human; nootropic; neuroprotective; cytosolic; dermatological; virucide;
XX immunosuppressive; antitubercular; anti-HIV; antibacterial; vulnerary;
XX antiparkinsonian; antischistosomal; antianemic; antiarthritic; cancer;
XX antitubercular; hepatotropic; cerebroprotective; antiinflammatory;
XX antiallergic; antidiabetic; antitumor; anticonvulsant; antifungal;
XX antiparasitic; cardiac; immune disorder; cardiovascular disorder;
XX neurological disease; infection; nephrotropic; gene therapy; vaccine; ds.
XX OS Homo sapiens.
XX PN WO200159063-A2.
XX PD 16-AUG-2001.
XX PF 17-JAN-2001; 2001WO-US01334.
XX PR 31-JAN-2000; 2000US-0179065.
XX PR 04-FEB-2000; 2000US-0180628.
XX PR 24-FEB-2000; 2000US-0184664.
XX PR 02-MAR-2000; 2000US-0186350.
XX PR 16-MAR-2000; 2000US-0189874.
XX PR 17-MAR-2000; 2000US-0190076.
XX PR 18-APR-2000; 2000US-0198123.
XX PR 19-MAY-2000; 2000US-0205515.
XX PR 07-JUN-2000; 2000US-0209467.
XX PR 28-JUN-2000; 2000US-0214886.
XX PR 30-JUN-2000; 2000US-0215135.
XX PR 07-JUL-2000; 2000US-0216647.
XX PR 07-JUL-2000; 2000US-0216880.
XX PR 11-JUL-2000; 2000US-0217487.
XX PR 11-JUL-2000; 2000US-0217496.
XX PR 14-JUL-2000; 2000US-0218290.
XX PR 26-JUL-2000; 2000US-0220963.
XX PR 26-JUL-2000; 2000US-0220964.
XX PR 14-AUG-2000; 2000US-0224518.
XX PR 14-AUG-2000; 2000US-0224519.
XX PR 14-AUG-2000; 2000US-0225213.
XX PR 14-AUG-2000; 2000US-0225214.
XX PR 14-AUG-2000; 2000US-0225266.
XX PR 14-AUG-2000; 2000US-0225267.
XX PR 14-AUG-2000; 2000US-0225268.
XX PR 14-AUG-2000; 2000US-0225270.
XX PR 14-AUG-2000; 2000US-0225270.
XX PR 14-AUG-2000; 2000US-0225447.
XX PR 14-AUG-2000; 2000US-0225757.
XX PR 14-AUG-2000; 2000US-0225758.
XX PR 14-AUG-2000; 2000US-0225759.
```


PR 18-AUG-2000; 2000US-0226779.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226688.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228824.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231245.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 12-SEP-2000; 2000US-0232081.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239337.
PR 13-OCT-2000; 2000US-0239337.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 20-OCT-2000; 2000US-0242221.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.

PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250391.
PR 01-DEC-2000; 2000US-0251160.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259676.

PA (HUMA-) HUMAN GENOME SCI INC.
XX Rosen CA, Barash SC, Ruben SM.
XX WPI: 2001-541565/60.
XX
DR Nucleic acids encoding 3224 human nervous system antigen polypeptides,
XX useful for preventing, diagnosing and/or treating nervous system
XX cancers and metastases -
XX
PS Disclosure: SEQ ID NO 10304; 1701pp + Sequence Listing: English.
XX
CC The invention relates to novel genes (ABA11004-ABA21534) and proteins
CC (ABA14678-ABA18001) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (ant)agonists are useful
CC in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
CC and ovarian cancer and other cancers of the adrenal gland, bone, bone
CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
CC (b) immune disorders e.g. Addison's disease, allergies, autoimmune
CC haemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative
CC colitis; (c) cardiovascular disorders such as myocardial ischaemia; and
CC (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
CC epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
CC and parasitic infections.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pcl_sequences.
XX
SQ Sequence 3660 BP; 981 A; 820 C; 984 G; 875 T; 0 other;
XX
Query Match 5.8%; Score 209; DB 22; Length 3660;
Best Local Similarity 80.3%; Pred. No. 1.9e-34;
Matches 245; Conservative 0; Mismatches 60; Indels 0; Gaps 0;
OY 1084 TATTTATTTATTTATTTGAGAGAGCTGCTGCTGCGCCAGGCTGAGTGCAGCGG 1143
I III III III IIIIIIIII I II IIIII IIIIIIIIIIIIIIIII II

Db 3220 TTTTTTTTTTTTTTTTTTTTGGAGAGCTCCTGTCCTCCAGGCTGGAGTGCAGTGG 3161
QY 1144 CGTGAATCAGATTCTACTGACGCTTCACACTTCTAGGCTCAAGGATTTCTCCACCTGAGC 1203
Db 3160 CGTGATCTCGGTCACGACACCTCCACCTCCAGGTTCAAGGATTTCTCTGCTGAGC 3101
QY 1204 CCCCCAAGTAGTTGGAGCACACGATGCGCCACATGCTGGCTAATTTCTATTATTTTTT 1263
Db 3100 CTCCCAAGTAGTGGGACTATGAGCATGCGCTACCATGCCCCGGCTAATTTTATATTTTTT 3041
QY 1264 TGTAGAGATGGATCTCATATATTTGTCAGGCTGCTGTGAATTCCTGGGCTCAGGTGA 1323
Db 3040 AGTAGAGACAGGATTTACATGTTGGCCAGGCTGCTTGAATCTGATTTCAAGTGA 2981
QY 1324 GCCTCCACCTGGGCTCCCAAGTACTGGGATTACAGCATGAGCCAAAGTCCCTGCC 1383
Db 2980 TGCACCCACCTCGGCTCCCAAGTGTGGGATTACAGGCTGAGCATGCTGACGCGCC 2921
QY 1384 CATAT 1388
Db 2920 AAAAT 2916

RESULT 6
ABAI7972/c
ID ABAI7972 standard; DNA; 3662 BP.
XX
AC ABAI7972;
XX
DT 23-JUN-2002 (first entry)
XX
DE Human nervous system related polynucleotide SEQ ID NO 10303.
XX
KW Human; nootropic; neuroprotective; cyostatic; dermatological; virologic;
KW immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnery;
KW antiparkinsonian; antislaking; antianaemic; antiarthritic; cancer;
KW antineumatic; hepatotropic; cerebroprotective; antiinflammatory;
KW antiallergic; antidiabetic; antilucer; anticonvulsant; antifungal;
KW antiparasitic; cardiatic; immune disorder; cardiovascular disorder;
KW neurological disease; infection; nephrotropic; gene therapy; vaccine; ds.
XX
OS Homo sapiens.
XX
PN WO200159063-A2.
XX
PD 16-AUG-2001.
XX
PF 17-JAN-2001; 2001MO-US01334.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220863.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.

PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226688.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229519.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 12-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234497.
PR 25-SEP-2000; 2000US-0234498.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239335.
PR 13-OCT-2000; 2000US-0239337.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0244674.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.

PR	08-NOV-2000	2000US-0246527
PR	08-NOV-2000	2000US-0246532
PR	08-NOV-2000	2000US-0246532
PR	08-NOV-2000	2000US-0246609
PR	08-NOV-2000	2000US-0246610
PR	08-NOV-2000	2000US-0246611
PR	08-NOV-2000	2000US-0246613
PR	17-NOV-2000	2000US-0249207
PR	17-NOV-2000	2000US-0249208
PR	17-NOV-2000	2000US-0249209
PR	17-NOV-2000	2000US-0249210
PR	17-NOV-2000	2000US-0249211
PR	17-NOV-2000	2000US-0249212
PR	17-NOV-2000	2000US-0249213
PR	17-NOV-2000	2000US-0249214
PR	17-NOV-2000	2000US-0249215
PR	17-NOV-2000	2000US-0249216
PR	17-NOV-2000	2000US-0249217
PR	17-NOV-2000	2000US-0249218
PR	17-NOV-2000	2000US-0249244
PR	17-NOV-2000	2000US-0249245
PR	17-NOV-2000	2000US-0249264
PR	17-NOV-2000	2000US-0249265
PR	17-NOV-2000	2000US-0249297
PR	17-NOV-2000	2000US-0249299
PR	17-NOV-2000	2000US-0249300
PR	01-DEC-2000	2000US-0250391
PR	01-DEC-2000	2000US-0251160
PR	05-DEC-2000	2000US-0251130
PR	05-DEC-2000	2000US-0251988
PR	05-DEC-2000	2000US-0256179
PR	06-DEC-2000	2000US-0251179
PR	08-DEC-2000	2000US-0251856
PR	08-DEC-2000	2000US-0251858
PR	08-DEC-2000	2000US-0251869
PR	08-DEC-2000	2000US-0251989
PR	08-DEC-2000	2000US-0251990
PR	11-DEC-2000	2000US-0254097
PR	05-JAN-2001	2001US-0259678

PA (HUMA-) HUMAN GENOME SCI INC.
XX
XX
PI Rosen CA, Barash SC, Ruben SM,
XX
DR WPI; 2001-541565/60.

PT Nucleic acids encoding 3224 human nervous system antigen polypeptides
PT useful for preventing, diagnosing and/or treating nervous system
PT cancers and metastases -

PS Disclosure; SEQ ID NO 10303; 1701pp + Sequence Listing; English.

CC The invention relates to novel genes (ABAI1004-ABR21534) and proteins
CC (ABAI4678-ABR18001) useful for preventing, treating or ameliorating
CC medical conditions e.g. by protein or gene therapy. The genes are
CC isolated from a range of human tissues disclosed in the specification.
CC The nucleic acids, proteins, antibodies and (anti)synonists are useful
CC in the diagnosis, treatment and prevention of: (a) cancer, e.g. breast
CC and ovarian cancer and other cancers of the adrenal gland, bone, bone
CC marrow, breast, gastrointestinal tract, liver, lung, or urogenital;
CC (b) immune disorders e.g. Addison's disease, allergies, autoimmune
CC hemolytic anaemia, autoimmune thyroiditis, diabetes mellitus, Crohn's
CC disease, multiple sclerosis, rheumatoid arthritis and ulcerative
CC colitis; (c) cardiovascular disorders such as myocardial ischaemias;
CC (d) wound healing; (e) neurological diseases e.g. cerebral anoxia and
CC epilepsy; and (f) infectious diseases such as viral, bacterial, fungal
CC and parasitic infections.
CC Note: The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pat_sequences.
XX
XX Sequence 3662 BP; 982 A; 820 C; 985 G; 875 T; 0 other;
XQ

	Query Match	5.88;	Score 209;	DB 22;	Length 3662;
	Best Local Similarity	80.38;	Pred. No. 1.9e-34;		
	Matches 245;	Conservative	0;	Mismatches 60;	Indels 0;
				Gaps	
QY	1084 TATTATTATTTATTTATTTTGGAGATGAGACCTGGCTGGCCAGAGCTGGATGCGACGG			1143	
Db	3222 TTTTTTTTTTTTTTTTTTTTTTGAGAGAGCTCTCACTCTGTGTCTCAGGCTTGGAGTGG			3163	
QY	1144 CGTGTACAGAGTTTCACCTGACGACCTTCACCACTTTCAGGCTCAAGSGATTTCGCCACCTCAGC			1203	
Db	3162 CGTGTATCGGGCTACCTGACCACTCCACGCTCCAGGTTCAAGGATTCCTCGCTCAGC			3103	
QY	1204 CCCCCAGTAGTTGGGACCCACAGCTATGGGCCACACCTGCTGGCTTAATTTCTTATTTTTT			1263	
Db	3102 CTCCCAAGTAGCTGGGACTATAGGCATGGCCCTACCTGCGCCGGCTAAATTTTATTTT			3043	
QY	1264 TGTGAGATGAGATCTACATATATTTGCCAGCTGGCTTTGAATTCCTGGGCTCAGGTGA			1323	
Db	3042 AGTAGACACAGATTTTACCATGTTGGCCAGGCTGGTCTTGAACCTCTGATTTTCAAGTGA			2983	
QY	1324 GCTCCGACCTGGGCTCCCAAGATCTGGGATTACAGGATGAGCCACAGGTCCCTGCC			1383	
Db	2982 TGCACCCACCTCGGCTCCCAAGTGTGGATTACAGGCTGAGGCAATGCTGACCGGCC			2923	
QY	1384 CATAT 1388				
Db	2922 AAAAT 2918				

RESULT 7
AAV57926/c
ID AAV57926 standard; DNA; 235033 BP.

XX	
DT	23-DEC-1998 (first entry)

DE Hereditary haemochromatosis subregion from an unaffected individual.

KM Bovine butyrophilin; BT; human hereditary haemochromatosis; HFE;
KM diagnosis; Iron metabolism; NPT3; NPT4; RoRet; BTF1; BTF2; BTF3;
KW BTF4; BTF5; milk protein; lupus; Sjogren's syndrome; hypophosphatemia
KM type 1 sodium transport gene; ss.

OS Homo sapiens

PN W09814466-A1

PD 09-APR-1998.

PF 30-SEP-1997; 97WO-US17658.

PR 07-MAY-1997; 97US-0852495.

XX XX

XX

PI Tsuchihashi Z, Wolff RK;

DR WPI; 1998-240014/21.

PT Hereditary haemochromatosis gene products - used to develop products

PT metabolism

PS Example 2; Fig 8; 209pp; English.

CC The present invention describes hereditary haemochromatosis gene
CC products from the human haemochromatosis gene. The present sequence
CC represents a hereditary haemochromatosis subregion from an individual
CC unaffected by hereditary haemochromatosis (HH). Also described is a
CC method to determine the presence or absence of the common hereditary

DB 1117 CCCGCCAAGACATTCGGTATACATTAAAGTGAATGTTTATACATGAGT 1062
RESULT 11
ABA21094/C
ID ABA21094 standard; DNA; 1273 BP.
XX
AC ABA21094;
XX
DT 23-JAN-2002 (first entry)
XX
DE Human nervous system related polynucleotide SEQ ID NO 13425.
XX
KW Human; nocotropic; neuroprotective; cytostatic; dermatological; viroicide;
KW immunosuppressive; antiinflammatory; anti-HIV; antibacterial; vulnecary;
KW antiparthenonian; antistickling; antihaemetic; antiarthritic; cancer;
KW antirheumatic; hepatocytic; cerebroprotective; antiinflammatory;
KW antiallergic; antidiabetic; antitumor; anticonvulsant; antifungal;
KW antiparasitic; cardiant; immune disorder; cardiovascular disorder;
KW neurological disease; infection; nephrotropic; gene therapy; vaccine; ds.
XX
OS Homo sapiens.
XX
PN WO200159063-A2.
XX
PD 16-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01334.
XX
XX 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205815.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.

PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 12-SEP-2000; 2000US-0232081.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 20-OCT-2000; 2000US-0242221.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246538.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.

PR	20-OCT-2000;	2000US-0241809.
PR	20-OCT-2000;	2000US-0241826.
PR	01-NOV-2000;	2000US-0244617.
PR	08-NOV-2000;	2000US-0246474.
PR	08-NOV-2000;	2000US-0246475.
PR	08-NOV-2000;	2000US-0246476.
PR	08-NOV-2000;	2000US-0246477.
PR	08-NOV-2000;	2000US-0246478.
PR	08-NOV-2000;	2000US-0246523.
PR	08-NOV-2000;	2000US-0246524.
PR	08-NOV-2000;	2000US-0246525.
PR	08-NOV-2000;	2000US-0246526.
PR	08-NOV-2000;	2000US-0246511.
PR	08-NOV-2000;	2000US-0246613.
PR	17-NOV-2000;	2000US-0249207.
PR	17-NOV-2000;	2000US-0249208.
PR	17-NOV-2000;	2000US-0249209.
PR	17-NOV-2000;	2000US-0249210.
PR	17-NOV-2000;	2000US-0249211.
PR	17-NOV-2000;	2000US-0249212.
PR	17-NOV-2000;	2000US-0249213.
PR	17-NOV-2000;	2000US-0249214.
PR	17-NOV-2000;	2000US-0249215.
PR	17-NOV-2000;	2000US-0249216.
PR	17-NOV-2000;	2000US-0249217.
PR	17-NOV-2000;	2000US-0249218.
PR	17-NOV-2000;	2000US-0249244.
PR	17-NOV-2000;	2000US-0249245.
PR	17-NOV-2000;	2000US-0249264.
PR	17-NOV-2000;	2000US-0249265.
PR	17-NOV-2000;	2000US-0249297.
PR	17-NOV-2000;	2000US-0249299.
PR	17-NOV-2000;	2000US-0249300.
PR	01-DEC-2000;	2000US-0250160.
PR	01-DEC-2000;	2000US-0250391.
PR	05-DEC-2000;	2000US-0251030.
PR	05-DEC-2000;	2000US-0251988.
PR	05-DEC-2000;	2000US-0256719.
PR	06-DEC-2000;	2000US-0251479.
PR	08-DEC-2000;	2000US-0251856.
PR	08-DEC-2000;	2000US-0251868.
PR	08-DEC-2000;	2000US-0251869.
PR	08-DEC-2000;	2000US-0251989.
PR	08-DEC-2000;	2000US-0251990.
PR	11-DEC-2000;	2000US-0254097.
PR	05-JAN-2001;	2001US-0259678.
PA	(HUMA-) HUMAN GENOME SCI INC.	
XX		
PI	Rosen CA, Barash SC, Ruben SM;	
XX		
DR	WPI: 2001-483426/52.	
XX		
PT	Nucleic acids encoding human immune/hematopoietic antigen polypeptides	
PT	useful for preventing, diagnosing and/or treating cancers and	
PT	metastasis -	
XX		
PS	Disclosure; SEQ ID NO 38141; 3071bp + Sequence Listing; English.	
XX		
CC	AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)	
CC	amino acid sequences given in AAM82170 to AAM91921. (I) have cytoskeletal	
CC	activity, and can be used in gene therapy and vaccine production. (I)	
CC	proteins and polynucleotides may be used in the prevention, diagnosis a	
CC	treatment of diseases associated with inappropriate (I) expression. For e	
CC	xample, they may be used to treat disorders associated with decreased	
CC	expression by rectifying mutations or deletions in a patient's genome	
CC	that affect the activity of (I) by expressing inactive proteins or to	
CC	supplement the patient's own production of (I). Additionally, (I)	

[illegible]

FT	intron	/number-1
FT		3360..4259
FT		/*tag= e
FT	exon	/number-1
FT		4260..4307
FT		/*tag= f
FT	intron	/number-2
FT		4308..4749
FT		/*tag= g
FT	exon	/number-2
FT		4750..4803
FT		/*tag= h
FT	intron	/number-3
FT		4804..5206
FT		/*tag= i
FT	exon	/number-3
FT		5207..5258
FT		/*tag= j
FT	intron	/number-4
FT		5259..5511
FT		/*tag= k
FT	exon	/number-4
FT		5512..5645
FT		/*tag= l
FT	intron	/number-5
FT		5646..6122
FT		/*tag= m
FT	exon	/number-5
FT		6123..6159
FT		/*tag= n
FT	intron	/number-6
FT		6160..7038
FT		/*tag= o
FT	exon	/number-6
FT		7039..7060
FT		/*tag= p
FT	intron	/number-7
FT		7061..8252
FT		/*tag= q
FT	exon	/number-7
FT		8253..8341
FT		/*tag= r
FT	intron	/number-8
FT		8342..12264
FT		/*tag= s
FT	variation	relace (8868, G)
FT		/*tag= t
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (10187, G)
FT		/*tag= u
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (10216, C)
FT		/*tag= v
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (11100, A)
FT		/*tag= w
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (11650, A)
FT		/*tag= x
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (11656, C)
FT		/*tag= y
FT	exon	/standard_name="single nucleotide polymorphism"
FT		12265..12464
FT		/*tag= z
FT	intron	/number-9
FT		12465..15226
FT		/*tag= aa
FT	variation	/number-9
FT		relace (15095, T)
FT		/*tag= ab
FT		/standard_name="single nucleotide polymorphism"

FT	variation	relace (15116, G)
FT		/*tag= ac
FT	exon	/standard_name="single nucleotide polymorphism"
FT		15227..15280
FT		/*tag= ad
FT	intron	/number-10
FT		15281..16061
FT		/*tag= ae
FT	variation	/number-10
FT		relace (15428, G)
FT		/*tag= af
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (15827, C)
FT		/*tag= ag
FT	exon	/standard_name="single nucleotide polymorphism"
FT		16062..16135
FT		/*tag= ah
FT	variation	/number-11
FT		relace (16135, A)
FT		/*tag= ai
FT	intron	/standard_name="single nucleotide polymorphism"
FT		16136..18797
FT		/*tag= aj
FT	variation	/number-11
FT		relace (16557, A)
FT		/*tag= ak
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (17375, C, T, G, A)
FT		/*tag= al
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (17511, C, T)
FT		/*tag= am
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (17928, C)
FT		/*tag= an
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (17968, G)
FT		/*tag= ao
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (18574, C)
FT		/*tag= ap
FT	exon	/standard_name="single nucleotide polymorphism"
FT		18798..18885
FT		/*tag= aq
FT	intron	/number-12
FT		18886..19070
FT		/*tag= ar
FT	exon	/number-12
FT		19071..19199
FT		/*tag= as
FT	intron	/number-13
FT		19200..22830
FT		/*tag= at
FT	variation	/number-13
FT		relace (19654, T)
FT		/*tag= au
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (21498, T)
FT		/*tag= av
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (22729, A)
FT		/*tag= aw
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (22757, T)
FT		/*tag= ax
FT	variation	/standard_name="single nucleotide polymorphism"
FT		relace (22779, T)
FT		/*tag= ay
FT	exon	/standard_name="single nucleotide polymorphism"
FT		22831..22934
FT		/*tag= az
FT	intron	/number-14
FT		22935..26558

[illegible]

PA (HOMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM:
XX
DR WPI: 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
XX useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure: SEQ ID NO 34572; 3071pp + Sequence Listing: English.
XX
CC AAK54951 to AAK64702 encode the human immune/hematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patient's own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/hematopoietic-related diseases, especially
CC cancers and cancer metastases of hematopoietic-derived cells. AAK64703
CC to AAK87594 represent human immune/hematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
XX Sequence 20601 BP; 5874 A; 4297 C; 4363 G; 6067 T; 0 other;

Query Match	5.7%;	Score 204.8;	DB 22;	Length 20601;
Best Local Similarity	76.9%;	Pred. No. 2.4e-33;		
Matches 263;	Conservative	0;	Mismatches 77;	Indels 2;
			Gaps	1.
QY 1064	TTTTTAATTTTAAATTTATTTATTTATTTATTTTGTGATGGAGTCGG--CTGT	1121		
Db 19756	TTACACATATTTCTTTTATTTTATTTTATTTTATTTTGTGATAGAGGTCTGGCTCTT	19697		
QY 1122	CGCCACAGCTGGAGTGCAGCGCGCTGATCACAGTTCTACTCAGCACTCAACCTTCTAGCT	1181		
Db 19696	TGCCACAGCTGGAGTGCAGTGCAGTGCAGTATCTCAGCTACACCTCTCTCCCTCTAGGCT	19637		
QY 1182	CAAGGAAATTCCTCCACCTCAGCCGCCCAAGTAGTTGGAGCAACAGCTATGGCCACCATG	1241		
Db 19636	CAGGCATCTTCTCTCCTCAGCTCCCAAGTAGCTGGAGCTCAGGTGCATGCCACCATG	19577		
QY 1242	CCTGGCTAATTTCTATTTTGTGAGAGATAGATCTACATATTTGTCCAGGCTGGTC	1301		
Db 19576	CCTGGCTAATTTTGTATTTCTGTGAGACAGAGGTTTGCCATGTGTGCCACAGACTGGTC	19517		
QY 1302	TTGAAATTCCTGGGCTCAGGTGAGCTCCCACTGGGCTCCCAAGATCTGGATTTACAG	1361		
Db 19516	TGGAACTCTGTAGCTCAACAGCATCTCTTGCCCAAGGCTCCCAAGTGCTGGGATTACAG	19457		
QY 1362	GCATGAGCCAAAGTCCCTGGCCCATATGAGATTTTCTGTCTC	1403		
Db 19456	GCATGAGCCACATGTGCTCCAGCTGTGGATTCATATTTCTGGCTC	19415		

Search completed: February 24, 2003, 14:33:36
Job time : 1458.05 secs

XX
PR 05-JAN-2001; 2001US-0259678.
XX

